ArticleNature communications2025
Assessing the risk of Guillain-Barré syndrome in older adults after bivalent RSV pre-F vaccination in England.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A narrative review of considerations when assessing potential relationships between Guillain-Barré syndrome and vaccines.Human vaccines & immunotherapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An elevated risk of Guillain-Barré syndrome following respiratory syncytial virus vaccination in older adults was reported from the United States in the first year of their programme. This national study assesses the risk of Guillain-Barré syndrome (GBS) following vaccination against respiratory syncytial virus (RSV) using bivalent pre-F (Abrysvo, Pfizer) vaccine in England's programme for 2.5 million 75-79 year olds. The vaccination campaign began in September 2024, with initial risk assessed three months later using the intravenous immunoglobulin registry for the target age group. This ecological analysis used historical data and case-coverage comparisons linking to the national RSV vaccine register. A final six-month analysis combined the intravenous immunoglobulin and GBS-coded hospital discharge data, using both case-coverage and the planned self-controlled case-series method, focusing on the 0-42 day post-vaccination risk window. The initial analysis showed a significant increased risk of GBS after RSV vaccination, confirmed by both ecological and case-coverage methods. Final results were consistent, with the self-controlled case-series estimating a relative incidence of 3.34 (95% CI: 2.12-5.28) and an attributable risk of 23 (95% CI: 17-26) cases per million doses. Here, we show a small risk of GBS following RSV vaccination with the bivalent pre-F in England's older adults' programme, but this is at a level that is far exceeded by the vaccine benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.